CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma

Neuro-Oncology

Volumn 17, Issue 11, 2015, Pages 1497-1503

  Viaccoz, Aurélien ^a,b,c   Ducray, François ^a,b,c   Tholance, Yannick ^a,b   Barcelos, Gleicy Keli ^b,d   Thomas Maisonneuve, Laure ^a,b,c   Ghesquières, Hervé ^e   Meyronet, David ^b   Quadrio, Isabelle ^a,b   Cartalat Carel, Stéphanie ^a   Louis Tisserand, Guy ^a   Jouanneau, Emmanuel ^a   Guyotat, Jacques ^a   Honnorat, Jérôme ^a,b,c   Perret Liaudet, Armand ^a,b  

^a HÔPITAL NEUROLOGIQUE   (France)

^b LYON NEUROSCIENCE RESEARCH CENTER   (France)

^c UNIVERSITÉ LYON 1   (France)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

biomarker; cerebrospinal fluid; neopterin; primary central nervous system lymphoma; space occupying brain lesion

Indexed keywords

NEOPTERIN; TUMOR MARKER;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADULT; AGED; ANAPLASTIC GLIOMA; ANAPLASTIC MENINGIOMA; ANTI LEUCINE RICH GLIOMA INACTIVATED 1 ENCEPHALITIS; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ARTICLE; BRAIN METASTASIS; BRAIN PSEUDOTUMOR; BRAINSTEM GLIOMA; CELL COUNT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENCEPHALITIS; FEMALE; GERM CELL TUMOR; GLIOBLASTOMA; GLIOMA; HEMANGIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PARANEOPLASTIC NEUROPATHY; PINEAL BODY TUMOR; PREDICTIVE VALUE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN CEREBROSPINAL FLUID LEVEL; RETROSPECTIVE STUDY; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; VASCULAR AMYLOIDOSIS; ADOLESCENT; CENTRAL NERVOUS SYSTEM NEOPLASMS; CEREBROSPINAL FLUID; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LYMPHOMA; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPTERIN; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84944123798     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov092     Document Type: Article

References (32)

1. Baraniskin A, Deckert M, Schulte-Altedorneburg G, et al. Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. Br J Haematol. 2012;156(4):421-432.
2. Ricard D, Idbaih A, Ducray F, et al. Primary brain tumours in adults. Lancet. 2012;379(9830):1984-1996.
3. Hagberg L, Dotevall L, Norkrans G, et al. Cerebrospinal fluid neopterin concentrations in central nervous system infection. J Infect Dis. 1993;168(5):1285-1288.
4. Lezin A, Buart S, Smadja D, et al. Tissue inhibitor of metalloproteinase 3, matrix metalloproteinase 9, and neopterin in the cerebrospinal fluid: preferential presence in HTLV type I-infected neurologic patients versus healthy virus carriers. AIDS Res Hum Retroviruses. 2000;16(10):965-972.
5. Dotevall L, Fuchs D, Reibnegger G, et al. Cerebrospinal fluid and serum neopterin levels in patients with Lyme neuroborreliosis. Infection. 1990;18(4):210-214.
6. Bagnato F, Durastanti V, Finamore L, et al. Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis. Neurol Sci. 2003;24(suppl 5):S301-S304.
7. Tsolaki KK, Zaphiriou D, Grammaticos P, et al. Are CSF neopterin levels a marker of disease activity in multiple sclerosis? Nucl Med Rev Cent East Eur. 2001;4(2):109-111.
8. Furukawa Y, Nishi K, Kondo T, et al. Significance of CSF total neopterin and biopterin in inflammatory neurological diseases. J Neurol Sci. 1992;111(1):65-72.
9. Widner B, Leblhuber F, Fuchs D. Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J Neural Transm. 2002;109(2):181-189.
10. Lenzlinger PM, Hans VH, Joller-Jemelka HI, et al. Markers for cell-mediated immune response are elevated in cerebrospinal fluid and serum after severe traumatic brain injury in humans. J Neurotrauma. 2001;18(5):479-489.
11. Quadrio I. Nouveaux développements moléculaires et technologiques pour le diagnostic des maladies à prions du vivant du patient. Thesis. Université Claude-Bernard Lyon 1, Lyon, France; 2008.
12. Stoeck K, Zerr I. Cellular immune activation markers neopterin and beta2-microglobulin are not elevated in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neuroimmunol. 2011; 233(1-2):228-232.
13. Perret-Liaudet A, Boibieux A, Gabet J, et al. CSF neopterin in neurological disease in HIV-1 infection. PoB 3497, VIII International Conference on AIDS/III STD world Congress, Amsterdam, Netherlands, 1992.
14. Hoffmann G, Frede S, Kenn S, et al. Neopterin-induced tumor necrosis factor-alpha synthesis in vascular smooth muscle cells in vitro. Int Arch Allergy Immunol. 1998;116(3):240-245.
15. Hoffmann G, Rieder J, Smolny M, et al. Neopterin-induced expression of intercellular adhesion molecule-1 (ICAM-1) in type II-like alveolar epithelial cells. Clin Exp Immunol. 1999;118(3): 435-440.
16. Dobson R, Topping J, Davis A, et al. Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. Acta Neurol Scand. 2013;128(5): 321-327.
17. Murr C, Widner B, Wirleitner B, et al. Neopterin as a marker for immune system activation. Curr Drug Metab. 2002;3(2):175-187.
18. Caenazzo A, Pietrogrande F, Sgarabotto D, et al. Serum neopterin levels in haematological malignancies. Haematologica. 1993; 78(4):225-229.
19. Millot F, Dhondt JL, Mazingue F, et al. Cerebrospinal fluid neopterin levels in children with central nervous system leukemia. Leuk Lymphoma. 1993;9(4-5):351-356.
20. Reibnegger G, Fuchs D, Fuith LC, et al. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev. 1991;15(6):483-490.
21. Sucher R, Schroecksnadel K, Weiss G, et al. Neopterin, a prognostic marker in human malignancies. Cancer Lett. 2010; 287(1):13-22.
22. Komohara Y, Horlad H, Ohnishi K, et al. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J Clin Exp Hematop. 2011;51(2):93-99.
23. Kitai R, Ishisaka K, Sato K, et al. Primary central nervous system lymphoma secretes monocyte chemoattractant protein 1. Med Mol Morphol. 2007;40(1):18-22.
24. Hofmann B, Bass H, Nishanian P, et al. Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha. Clin Exp Immunol. 1992;88(3):548-554.
25. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984; 160(1):310-316.
26. Kersten MJ, Evers LM, Dellemijn PL, et al. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. Blood. 1996;87(5):1985-1989.
27. Caudie C, Bancel J, Dupont M, et al. [CSF levels and diagnostic utility of cerebrospinal fluid beta2-microglobulin]. Ann Biol Clin (Paris). 2005;63(6):631-637.
28. Roy S, Josephson SA, Fridlyand J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008;26(1):96-105.
29. Schroers R, Baraniskin A, Heute C, et al. Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. Eur J Haematol. 2010; 85(3):236-242.
30. Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of micro RNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117(11):3140-3146.
31. Sasayama T, Nakamizo S, Nishihara M, et al. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro Oncol. 2012;14(3):368-380.
32. Rubenstein JL, Wong VS, Kadoch C, et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013;121(23):4740-4748.